Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • EMEA approvals 2018

    - PMLiVE

    Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis

    Approximately 125 million people globally are living with some form of psoriasis

    - PMLiVE

    Johnson & Johnson’s Darzalex approved by EC as first treatment for high-risk SMM

    The early precursor of active multiple myeloma accounts for around 15% of all new multiple myeloma cases

    - PMLiVE

    Johnson & Johnson’s TAR-200 granted FDA priority review to treat bladder cancer

    An estimated 84,870 people will be diagnosed with bladder cancer in the US this year

    - PMLiVE

    J&J’s Darzalex recommended by CHMP to treat smouldering multiple myeloma

    If approved, Darzalex would be the first therapy approved in the EU for SMM

    - PMLiVE

    Johnson & Johnson’s Tremfya granted EC approval to treat ulcerative colitis in adults

    More than 2.5 million people in Europe are living with the inflammatory bowel disease

    - PMLiVE

    J&J’s subcutaneous Darzalex regimen approved by EC for newly diagnosed multiple myeloma

    More than 35,000 people in the EU were diagnosed with the blood cancer in 2022

    - PMLiVE

    J&J’s Stelara granted EC approval to treat Crohn’s disease in paediatric patients

    Approximately 25% of cases are diagnosed during childhood or adolescence

    - PMLiVE

    Johnson & Johnson’s Tremfya recommended by CHMP to treat Crohn’s disease

    Inflammatory bowel disease is estimated to affect nearly two million people across Europe

    - PMLiVE

    J&J shares overall survival results for Rybrevant/Lazcluze combination in lung cancer

    The regimen was approved by the MHRA earlier this month to treat EGFR-mutated NSCLC

    - PMLiVE

    Johnson & Johnson to invest more than $55bn in US over next four years

    The commitment marks a 25% increase to the company's US investments in the past four years

    - PMLiVE

    Johnson & Johnson’s Tremfya granted FDA approval to treat Crohn’s disease

    An estimated three million people in the US are affected by inflammatory bowel disease

    - PMLiVE

    J&J/Protagonist’s icotrokinra shows promise in phase 3 plaque psoriasis programme

    More than 125 million people worldwide are estimated to be living with the immune-mediated skin disease

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links